Celltrion

- Early performance demonstrated with national tender wins in Norway and Denmark… Secured 35% share of the IV market in the Netherlands- The world’s first and only infliximab liquid formulation… Patent registrations completed across most European countries including the EU5- Continued field-friendly marketing activities through formulation innovation reflecting clinical needs… Enhancing brand value- The world’s first and only full infliximab portfolio of IV and SC formulations… “Will continue innovation in biosimilar products” [March 11, 2026, KST] Celltrion today announced the European launch of the liquid formulation of Remsima (infliximab), strengthening its leadership in the infliximab market. The infliximab liquid formulation is uniquely held by Celltrion globally and is supported by registered patents. As a newly introduced formulation reflecting clinical needs, it is expected to further reinforce Remsima’s influence through enhanced product competitiveness and expanded market impact. Celltrion’s Nordic affiliate achieved early success by securing contracts with the Remsima intravenous (IV) liquid formulation in infliximab national tenders held in Denmark and Norway. Following the European approval of the Remsima IV liquid formulation in November last year, the local affiliate had prepared in advance to ensure product distribution through key national tenders. As a result, sales in Norway began immediately after the tender award, with supply planned through January 2028. Through this, the product is expected to secure approximately 35% share of the infliximab IV market in Norway. The Remsima liquid formulation expands treatment options by reflecting clinical needs, alongside the existing Remsima IV (100 mg lyophilized formulation) and Remsima SC. In European clinical settings, there has been continuous demand for a multi-dose liquid formulation that enables more efficient storage and management while reducing the complexity of the preparation process. Reflecting these needs, Celltrion has introduced the Remsima 350 mg liquid formulation, while continuing to strengthen field-focused sales and marketing activities. With the field-friendly Remsima liquid formulation, healthcare institutions are expected to benefit from administrative and cost efficiencies, further strengthening the competitiveness of the Remsima portfolio. Compared with the lyophilized formulation, the liquid formulation can reduce preparation time by approximately 50%, while lowering labor and consumable costs by around 20% during drug preparation. In addition, storage space and related storage costs can be reduced by up to 70%, generating strong interest across Europe from the early stage of launch. The recent national tender award in Norway also reflects recognition of these advantages and is expected to serve as a new competitive strength for Remsima in Europe, where tender markets represent a significant portion of demand. Celltrion has also filed patents for the Remsima liquid formulation and has completed patent registrations in most European countries, including the EU5 markets such as the UK, Germany and France. As Remsima is the only infliximab product available in a liquid formulation, its differentiated competitiveness is expected to further strengthen its influence in the infliximab market. Following the development and commercialization of the world’s first infliximab SC formulation, Celltrion has now secured the IV liquid formulation, becoming the only company globally to establish a full portfolio of infliximab IV (lyophilized and liquid) and SC formulations. Based on this, the company aims to further strengthen brand trust in Remsima in the infliximab market, expand prescriptions across both Remsima IV and SC, and enhance profitability. In addition, Celltrion plans to continue product innovation reflecting clinical needs while reinforcing its differentiated corporate image with unique competitiveness in the biosimilar market. Starting with the Nordic region, Celltrion plans to expand the launch of the Remsima liquid formulation across Europe this year, including France, the Netherlands and the Czech Republic, further strengthening its leadership in the infliximab market. According to pharmaceutical market research firm IQVIA, the Remsima portfolio (IV and SC) maintained the No.1 position in infliximab prescriptions in Europe with a 68% market share as of Q3 last year. Based on the strengthened Remsima portfolio with a full formulation lineup, Celltrion plans to continue strengthening its market position while addressing diverse clinical needs. “As trust in Celltrion continues to build in the European biosimilar market, the Remsima liquid formulation reflects clinical needs and has demonstrated its competitiveness by securing tender wins immediately after launch," said Seung-doo Baek, Head of Celltrion’s Nordic affiliate. "Going forward, we will continue field-focused sales and marketing activities to provide better treatment options for patients and healthcare professionals in Europe while further expanding prescriptions.”

- Celltrion plans to expand treasury share cancellation to 9.11 million shares by adding 3 million shares originally reserved for employee compensation to the previously announced 6.11 million shares.- The total treasury share cancellation amounts to KRW 1.9268 trillion, representing the cancellation of 74% of the company’s total treasury shares to enhance shareholder value.- The decision reflects a proactive response to market volatility amid rising geopolitical risks and uncertainties, while reaffirming the company’s commitment to prioritizing shareholder value.- “We are prioritizing shareholder value amid heightened uncertainties and will make every effort to achieve this year’s revenue target of KRW 5.3 trillion,” a Celltrion official said. INCHEON, South Korea – Celltrion announced today that it has decided to expand treasury share cancellation to approximately 9.11 million shares and disclosed a revision to the agenda for its upcoming annual general meeting of shareholders. Based on the closing price on March 5, the total value of the shares to be cancelled amounts to approximately KRW 1.9268 trillion[1].In the agenda for the 35th annual general meeting of shareholders previously disclosed, Celltrion proposed a resolution titled “Approval of Treasury Share Holding and Disposal Plan and Cancellation,” which included the cancellation of approximately 6.11 million treasury shares, excluding shares reserved for stock option compensation. The approximately 3 million shares excluded from cancellation had been retained to fulfill stock option grants already awarded to certain employees. Through this latest disclosure, Celltrion proposed revising the agenda to include these stock option-related treasury shares as well, thereby increasing the total cancellation volume to approximately 9.11 million shares. Employee stock option compensation will be managed through new share issuances. However, as the treasury shares will be cancelled first and new shares issued afterward, the company expects no impact on the total number of shares outstanding. The approximately 9.11 million shares to be cancelled represent about 74% of the total treasury shares held by Celltrion. The remaining 3.23 million shares, equivalent to about 26%, will be utilized to support future growth initiatives. Celltrion’s decision to cancel nearly three quarters of its treasury shares reflects its longstanding commitment to prioritizing shareholder value. The decision also reflects the company’s response to heightened market volatility driven by increasing geopolitical risks. In fact, Celltrion has continued to implement shareholder-friendly initiatives in 2024 and 2025, including treasury share purchases and cancellations, as well as providing updates to shareholders on the company’s response to rapidly changing market conditions. In addition, the company plans to proactively reflect the intent of the amended Commercial Act at this year’s shareholders’ meeting by introducing measures such as an independent director system, mandatory cumulative voting, an increase in separately elected outside directors, and the adoption of electronic shareholder meetings, further strengthening the protection of shareholder rights. Other agenda items to be presented at the shareholders’ meeting include partial amendments to the articles of incorporation, appointment of directors, and approval of financial statements including a cash dividend of KRW 750 per share. The director appointment agenda has been revised to nominate Shin Min-chul, Head of the Administration Unit and President, as an internal director, replacing Kim Hyoung-ki, Vice Chairman and Head of the Global Sales Business Group, who has decided to step down due to personal reasons. In addition, part of the statement of appropriation of retained earnings has been revised to secure surplus for the additional treasury share cancellation. “The decision to cancel 9.11 million treasury shares, representing 74% of the company’s total treasury holdings including the additional amount announced today, reflects our commitment to prioritizing the protection of shareholder interests amid an unstable market environment,” a Celltrion official said. “We will continue to respond to market changes while conducting our business responsibly and enhancing shareholder value, and will make every effort to achieve this year’s revenue target of KRW 5.3 trillion.” [1] Closing price on March 5, KRW 211,500

- Celltrion seeks to create synergy in the obesity drug market through the development of a differentiated quadruple-action injectable and an oral drug.- The multi-target injectable, including GLP-1, is designed to improve the adverse event profile and maximize efficacy compared to existing therapies, with an IND submission planned for 2027.- The GLP-1–based oral drug is expected to significantly expand treatment access by improving patient compliance, with an IND submission planned for 2028.- Celltrion aims to establish a foundation for comprehensive market penetration through the development of two types of obesity therapies, tailored to patient characteristics and treatment stages. INCHEON, South Korea - Celltrion announced today that it is advancing the development of innovative obesity therapies differentiated from existing treatments, aiming to establish a strong position in the rapidly growing global obesity drug market. The company is implementing a dual-track strategy to simultaneously develop a quadruple-action injectable (development code: CT-G32), designed to maximize efficacy by expanding target mechanisms beyond existing therapies, and a multi-target oral therapy that significantly enhances dosing convenience compared to injectable treatments. The next-generation obesity therapeutic candidate CT-G32 is being developed as a first-in-class drug that simultaneously acts on four targets, surpassing the currently dominant GLP-1 (glucagon-like peptide-1)–based dual- and triple-agonists in the market. The candidate is designed to address limitations of existing therapies, including variable patient response and the loss of lean muscle mass, while maximizing appetite suppression and weight loss through its expanded multi-target mechanism. The company also plans to expand development into a metabolic disease therapy encompassing lipolysis promotion and regulation of energy metabolism. CT-G32 is currently undergoing preclinical studies for candidate compounds, with plans to submit an Investigational New Drug (IND) application in the first half of next year to initiate clinical trials. In parallel, the multi-target oral therapy currently under development is expected to significantly expand patient access by offering enhanced dosing convenience over injectables. Ease of storage and distribution, enabling sustained treatment, represents an additional advantage. While existing oral therapies either have limited accessibility due to their classification as psychotropic agents or offer relatively modest weight-loss effects, Celltrion is designing its candidate based on GLP-1 receptor agonists – a mechanism that has recently gained significant attention – as a best-in-class therapy. In particular, while recently emerging oral obesity therapies from global pharmaceutical companies act on a single GLP-1 receptor target, Celltrion’s oral therapy is being developed to act on multiple targets including the GLP-1 receptor, which is expected to deliver enhanced efficacy and reduced adverse events. Celltrion is currently conducting research to improve stability and bioavailability from both formulation and molecular design perspectives and plans to submit an IND application in the second half of 2028. Upon completion of development, Celltrion expects to establish itself as a game changer in the high-growth obesity treatment market based on improved efficacy and convenience compared to existing products. The injectable is being developed for patients requiring substantial initial weight loss or those with insufficient response to existing therapies, while the oral therapy is intended for patients who find injectables burdensome or those requiring long-term maintenance therapy following weight loss. Through this approach, the company aims to maximize synergy between the two therapies and establish a foundation for comprehensive market penetration across treatment stages. According to the World Health Organization (WHO), the global prevalence of overweight among adults has increased sharply from approximately 25% in the 1990s to over 40% in recent years. As a result, obesity-related complications and associated healthcare costs are rising. Market research firm GlobalData projects that the global obesity therapeutics market will reach approximately USD 173.5 billion by 2031. “Building on our established leadership in therapeutic areas such as autoimmune diseases and oncology, and following our recent expansion into ophthalmology and bone disorders, we plan to enter the obesity therapeutics market, which has immense growth potential, with differentiated competitiveness,” a Celltrion official said. “We will continue to actively explore new therapeutic areas, maximize corporate value, and strive to evolve into a global big pharma company.”